Featured AnalysisThe ICH Q11 Three-Part Justification — What FDA and EMA Require for Starting Material Designation and Where Programs Fall ShortXGene analysis · Aug 22, 2026Read Article →
Latest Warning LetterInside Genzyme’s Consent Decree: What the Terms Reveal About FDA’s Enforcement Standard and the Manufacturing System It Will AcceptWARNING LETTER · Aug 22, 2026Open Regulatory Record →
Featured AnalysisFDA Inspection Front Room Protocol — What to Say and What Not ToXGene analysis · Aug 22, 2026Read Article →
Latest Warning LetterInside Ranbaxy’s Consent Decree: What the Terms Reveal About FDA’s Enforcement Standard and the Manufacturing System It Will AcceptWARNING LETTER · Aug 22, 2026Open Regulatory Record →
CMC AnalysisSalt and Co-Crystal Selection: CMC Documentation of Pharmaceutical Form Decisions in Module 3XGene analysis · Aug 22, 2026Explore CMC Analysis →
FDA 483 SignalInside PharMEDium’s Consent Decree: What the Terms Reveal About FDA’s Enforcement Standard and the Manufacturing System It Will AcceptFDA 483 · Aug 22, 2026Open Regulatory Record →
Featured AnalysisPolymorphism in Drug Substances: The ICH Q6A Decision Tree, Solid-State Characterization, and Process-Induced Form Conversion RiskXGene analysis · Aug 22, 2026Read Article →
Regulatory SignalZhejiang Gaorong Cosmetic Co., Ltd. Added to Import Alert 66-40: The CGMP Pattern Behind the Detention and What Every Quality Director Managing Cross-Category Drug, Biologic, and Supplement Supply Chains Must KnowIMPORT ALERT · Aug 22, 2026Open Regulatory Record →
Featured AnalysisThe ICH Q11 Three-Part Justification — What FDA and EMA Require for Starting Material Designation and Where Programs Fall ShortXGene analysis · Aug 22, 2026Read Article →
Latest Warning LetterInside Genzyme’s Consent Decree: What the Terms Reveal About FDA’s Enforcement Standard and the Manufacturing System It Will AcceptWARNING LETTER · Aug 22, 2026Open Regulatory Record →
Featured AnalysisFDA Inspection Front Room Protocol — What to Say and What Not ToXGene analysis · Aug 22, 2026Read Article →
Latest Warning LetterInside Ranbaxy’s Consent Decree: What the Terms Reveal About FDA’s Enforcement Standard and the Manufacturing System It Will AcceptWARNING LETTER · Aug 22, 2026Open Regulatory Record →
CMC AnalysisSalt and Co-Crystal Selection: CMC Documentation of Pharmaceutical Form Decisions in Module 3XGene analysis · Aug 22, 2026Explore CMC Analysis →
FDA 483 SignalInside PharMEDium’s Consent Decree: What the Terms Reveal About FDA’s Enforcement Standard and the Manufacturing System It Will AcceptFDA 483 · Aug 22, 2026Open Regulatory Record →
Featured AnalysisPolymorphism in Drug Substances: The ICH Q6A Decision Tree, Solid-State Characterization, and Process-Induced Form Conversion RiskXGene analysis · Aug 22, 2026Read Article →
Regulatory SignalZhejiang Gaorong Cosmetic Co., Ltd. Added to Import Alert 66-40: The CGMP Pattern Behind the Detention and What Every Quality Director Managing Cross-Category Drug, Biologic, and Supplement Supply Chains Must KnowIMPORT ALERT · Aug 22, 2026Open Regulatory Record →
FDA Enforcement & GMP Remediation XGene CMC Intelligence FDA Enforcement & GMP Remediation Warning letters, 483 patterns, remediation and regulatory response. Featured analysis FDA 483 Recurring Observations — Pattern Recognition for CMC Teams Warning Letter Response — CMC Strategy Before the 15-Day Clock Starts PLZ Corp Warning Letter: Component Testing Failure and the CMC Pattern Every Quality Director Must Recognize Umendra Life Sciences Warning Letter: Component Testing Failures and the Talc-Asbestos Risk Every OTC CMC Director Must Recognize Sante Manufacturing Inc. Warning Letter: Raw Material Identity and Supplier Qualification Failures and the CMC Pattern Every OTC Drug Quality Director Must Recognize FDA 483 Equipment and Facilities — What Inspectors Actually Document Revlon Group Holdings Warning Letter: Component Testing and Laboratory Controls Failures and the CMC Pattern Every OTC Drug Quality Director Must Recognize FDA 483 Production and Process Controls — The CMC Risk Map Current regulatory intelligence Excelvision Warning Letter: Sterility Assurance Failure and the CMC Pattern Every Sterile Products Quality Director Must Recognize Babikian Healthcare Products Added to Import Alert 66-40: The CGMP Pattern Behind the Detention and What Every Quality Director Managing Dietary Supplement and OTC Drug Sites Must Know Inside PharMEDium’s Consent Decree: What the Terms Reveal About FDA’s Enforcement Standard and the Manufacturing System It Will Accept Zenzi Pharmaceutical Industries Faces FDA and EMA Simultaneously: What the Dual Enforcement Action Reveals About Global CGMP Standards and Your Supply Chain Risk Discuss an FDA Enforcement Response
PLZ Corp Warning Letter: Component Testing Failure and the CMC Pattern Every Quality Director Must Recognize
Umendra Life Sciences Warning Letter: Component Testing Failures and the Talc-Asbestos Risk Every OTC CMC Director Must Recognize
Sante Manufacturing Inc. Warning Letter: Raw Material Identity and Supplier Qualification Failures and the CMC Pattern Every OTC Drug Quality Director Must Recognize
Revlon Group Holdings Warning Letter: Component Testing and Laboratory Controls Failures and the CMC Pattern Every OTC Drug Quality Director Must Recognize
Excelvision Warning Letter: Sterility Assurance Failure and the CMC Pattern Every Sterile Products Quality Director Must Recognize
Babikian Healthcare Products Added to Import Alert 66-40: The CGMP Pattern Behind the Detention and What Every Quality Director Managing Dietary Supplement and OTC Drug Sites Must Know
Inside PharMEDium’s Consent Decree: What the Terms Reveal About FDA’s Enforcement Standard and the Manufacturing System It Will Accept
Zenzi Pharmaceutical Industries Faces FDA and EMA Simultaneously: What the Dual Enforcement Action Reveals About Global CGMP Standards and Your Supply Chain Risk
